Down regulation of bcl-2 by p53 in nasopharyngeal carcinoma and lack of detection of its specific t(14;18) chromosomal translocation in fixed tissues

Histopathology

Volumn 28, Issue 4, 1996, Pages 317-323

  Harn, H J ^a   Ho, L I ^b   Liu, C A ^a   Liu, G C ^a   Lin, F G ^a   Lin, J J ^a   Chang, J Y ^a   Lee, W H ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Apoptosis; bcl 2 protein; Nasopharyngeal carcinoma; p53 protein

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CHROMOSOME 14; CHROMOSOME 18; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0029879260     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1996.d01-431.x     Document Type: Article

References (40)

1. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57; 1083-1093.
2. Lane DP, Crawford L. T antigen is hound to a host protein in SV40-transformed cells. Nature 1979; 278; 261-263.
3. Scheffner M, Werness BA, Huibregste JM, Levine AJ, Howly PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes degradation of p53. Cell 1990; 63; 1129-1136.
4. Nigro JM, Baker SJ, Preisinger AC et al. Mutation in the p53 gene occur in diverse human tumor types. Nature 1989; 342; 705-708.
5. Takahashi T, Nau MM, Chiba I et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246; 491-494.
6. Baker SJ, Markowitz S, Fearon ER, Wilson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249; 912-915.
7. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990; 62; 671-680.
8. Diller L, Kassel J, Nelson C et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 1990; 10; 5772-5781.
9. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA 1992; 89; 4495-4499.
10. Wang Y, Szekely L, Okan I, Klein G, Wiman RG. Wild type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 1993; 8; 3427-3431.
11. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM.: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14:18) chromosome translocation. Science 1984; 226; 1097-1099.
12. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348; 324-336.
13. Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. New Engl. J. Med. 1982; 307; 1231-1236.
14. Adachi M, Tefferi A, Greipp PR, Kipps TJ, Tsujimoto Y. Preferential linkage of bcl-2 to immunoglobulin light-chain gene in chronic lymphocytic leukaemia. J. Exp. Med. 1990; 171; 559-564.
15. Seto M, Jaeger V, Kockett R et al. Alternative promoters and exons, somatic mutation and deregulation of the bcl-2-Ig fusion gene in lymphoma. EMBO J. 1988; 7; 123-131.
16. Mcdonnell T, Troncoso P, Brisbary S et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992; 52; 6940-6944.
17. Pezzella F, Turley H, Kuzu I et al. bcl-2 protein in non-small-cell lung carcinoma. N. Eng. J. Med. 1993; 329; 690-694.
18. Lui QL, Elia G, Lucas S, Thomas JA. Bcl-2 proto-oncogene expression in Epstein-Barr virus associated nasopharyngeal carcinoma. Int. J. Cancer 1993; 53; 29-35.
19. Effert P, McCoy R, Abdel-Hamid M et al. Alteration of the p53 gene in nasopharyngeal carcinoma. J. Virol. 1992; 66; 3768-3775.
20. Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor P53 is a regulator of bcl-2 and Bax gene expression in vitro and in vivo. Oncogene 1994; 9; 1799-1805.
21. Haldar S, Negrini M, Monne M, Sabbionio S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994; 54; 2095-2097.
22. Pezzella P, Gatter K. What is the value of bcl-2 protein detection for histopathologists? Histopathology 1995; 26; 89-93.
23. Sinicrope F, Ruan SB, Cleary KR et al. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995; 55; 237-241.
24. Wang Y, Szekely L, Okan I, Klein G, Wiman KG. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 1994; 8; 3421-3431.
25. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem. 1991; 39; 741-748.
26. Pezzella F, Tse AGD, Cordell JL, Pulford KA, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am. J. Pathol. 1990; 137; 225-232.
27. Zutter M, Hockenbery D, Silverman GA, Korsmeyer SJ. Immunolocalization of the bcl-2 protein within hematopoietic neoplasms. Blood 1991; 78; 1062-1068.
28. LeBrun DP, Kamel OW, Cleary ML, Dorfman RF, Warnke RA. Follicular lymphomas of the gastrointestinal tract. Pathologic features in 31 cases and bcl-2 oncogenic protein expression Am. J. Pathol. 1992; 140; 1327-1335.
29. Shibata D, Arnheim N, Martin WJ. Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction. J. Exp. Med. 1988; 239; 487-491.
30. Clearly ML, Smith SD, Sklar J. Cloning and structure analysis of cDNA for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14:18) translocation. Cell 1986; 47; 19-28.
31. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74; 957-9677.
32. Wang E, Friedman P, Prives C. The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell 1989; 57; 379-392.
33. Raycroft L, Wu H, Lozano G. Transcritional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 1990; 249; 1049-1051.
34. El-Deiry WS, Kern SE, Pietenpol JAQ, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1992; 1; 45-48.
35. Girsberg D, Mechta F, Yaniv M, Oren M. Wild-type p53 can down modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 1991; 88; 9979-9983.
36. Pezella F, Gatter KG, Mason UY. Detection of 14:18 chromosomal translocation in paraffin-embedded lymphoma tissue. Lancet 1989; 1; 779-780.
37. Bakhshi SA, Wright JJ, Graninger W et al. Mechanism of the t(14:18) chromosomal translocation: Structure analysis of both derivative 14 and 18 reciprocal partners. Proc. Natl. Acad. Sci. USA 1987; 84; 2396-2400.
38. Stetler-Stevenson M, Raffeld M, Cohen P, Cossman J. Detection of occult follicular lymphoma by specific DNA amplification. Blood 1988; 72; 1822-1825.
39. Lee M, Chang K, Cabanillas F, Freireich FJ, Trujillo JM, Stass SA. Detection of minimal residual cells carrying the t(14:18) by DNA sequence amplification. Science 1987; 237; 175-178.
40. Ngan B, Nourse J, Cleary ML. Detection of chromosomal translocation t(14:18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 1989; 73; 1759-1762.